Approaches that enhance solubility of challenging API to enable clinically viable formulations |
Discovery & preclinical approaches that enable rapid development |
Topics covered will include uses of technologies such as: amorphous solid dispersion, continuous granulation, coating and extrusion |
Innovative approaches to address oral delivery of biologics, including: proteins, peptides, nucleic acids, and beyond |
Tim Smith, Freund-Vector Corporation(More Info)
Bottom Spray (Wurster) Coating: Understanding the Challenges, Processing & Scale-Up Considerations – March 16th
Charles Vesey, Colorcon, Inc (More Info)
Formulation Strategies and Tools for Accelerated Development of Solid Oral Dosage Forms
– March 9th
Dr. Changquan Calvin Sun, University of Minnesota (UMN) (More Info)
Material-sparing and expedited development of tablets for early clinical testing
– April 13th
Wenzhan Yang, AstraZeneca (More Info)
Small Molecule Drug Delivery Approaches to Modulate Target Engagement in Drug Discovery
– TBD
|
Dr. Abu Serajuddin, St. John’s University University(More Info)
Title to be announced – March 2nd, 2021
Dr. Dave A. Miller, DisperSol Technologies
(More Info)
The Importance of Particle Properties on the Biopharmaceutical Performance of Amorphous Solid Dispersions – March 30th, 2021
Dr. Dana E. Moseson, Purdue University
(More Info)
Crystallinity: A Complex Critical Quality Attribute of Amorphous Solid Dispersions – May 11th, 2021
|
Dr. Ketan Patel, St. John’s University (More Info)
Development of self-medicated formulations of Remdesivir for COVID-19: Extended release in-situ depot and pulmonary liposome – April 6th
Dr. Sean McMahon, Ashland (More Info)
Extended Release Injectables: ViatelTM Bioresorbable Polymer Design for Success – Feb 23rd, 2021
Dr. Tom Tice, Evonik Corporation (More Info)
Lactide/Glycolide Parenteral Excipients for Successful Drug Delivery Solution – March 23rd, 2021
Dr. Mark A. Tracy, Tracy BioConsulting, LLC. (More Info)
Lessons Learned in Advancing Sustained Release Polymer Microparticle Products into the Clinic – May 4th, 2021
Dr. Jeffrey Leyton, Université de Sherbrooke (More Info)
Journey to the Center of the Cell: Reprogramming Intracellular Transport to the Nucleus Enhances Tumor Killing for Antibodies Conjugated to Nuclear-Active Payloads – TBD
|
Dr. Larry Ereshefsky, Hassman Research Institute and CNS Research(More Info)
Optimizing Formulations in Early Phase Development: The view from the ‘clinical’ side – TBD
|